09 April 2015
Who says bigger is better? According to a new report, mid-cap biotech companies are doing pretty well for themselves, thank you very much.
Combined revenues for 35 mid-sized biotechs shot up by 21.9% last year, according to new research from GlobalData. The cohort hiked its revenue haul to $26.5 billion last year, up from $24.8 billion in 2013.
Regeneron ($REGN) and Alexion ($ALXN) buoyed this year's numbers after posting banner top-line years. Regeneron's sales swelled by 34% in 2014 on the back of star eye med Eylea, as the Tarrytown, NY-based drugmaker continued its ex-U.S. push. And Alexion's ultra-pricey orphan drug Soliris generated $2.2 billion last year--leaping from 2013's $1.6 billion--thanks to higher volume of unit shipments, better-than-expected demand and a reimbursement pact with the French government, GlobalData analyst Adam Dion said in a statement.
It's not just a recent trend, either. According to GlobalData, between 2009 and 2013, revenues from the 35 mid-cap companies expanded by a compound annual growth rate of 25.2%
Larger companies are taking note, and one need look no further than AbbVie's ($ABBV) recent deal agreement for Pharmacyclics ($PCYC) to see that. Last month, the Illinois pharma said it would shell out $21 billion--a sum that shocked some analysts--for the cancer drugmaker after it netted nearly $493 million in new Imbruvica revenue.
Not all the midsize biotechs are cruising, though. Vertex Pharmaceuticals ($VRTX), in particular, fell hard last year as Big Pharma and Big Biotech pushed it around. Their hep C newcomers--Sovaldi from Gilead ($GILD) and Olysio from Johnson & Johnson's ($JNJ) Janssen--pushed Vertex's Incivek off the market, spurring a 52.1% revenue decline for the Massachusetts outfit.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024